Recce Pharmaceuticals Ltd. announced that in Cohort 5 of a Phase I clinical trial, R327 demonstrated a good safety and tolerability profile among 10 healthy male subjects intravenously dosed at 2,000mg. An Independent Safety Committee has unanimously approved Cohort 6 to commence at 4,000mg, with subjects recruited and dosing underway. The Phase I trial is an ascending dose, randomised, placebo-controlled, parallel, double-blind, single-dose study being conducted at Adelaide's CMAX clinical trial facility.

The study is evaluating the safety and pharmacokinetics of R327 in 7-10 healthy subjects per dose, across eight sequential dosing cohorts of 50-16,000mg. The study is on track to have all Phase I dosing complete by second quarter 2022.